Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | GLP1R | P43220 | 8/20 | 0.50 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.50 |
| ▸ | ALB | P02768 | 2/20 | 0.49 |
| ▸ | FNTA | P49354 | 1/20 | 0.49 |
| ▸ | FNTB | P49356 | 1/20 | 0.49 |
| ▸ | GNPAT | O15228 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13855520 | 0.90 | NOD1 (0.69) | FOLH1NOD1EPHX2GLP1R | |
| SCHEMBL10060822 | 0.90 | FOLH1 (0.81) | FOLH1NOD1GLP1R | |
| SCHEMBL13177561 | 0.90 | FOLH1 (0.81) | FOLH1NOD1GLP1R | |
| SCHEMBL20341058 | 0.89 | SIRT5 (0.63) | FOLH1ADRA1ANOD1EPHX2SIRT5 | |
| SCHEMBL25542854 | 0.88 | FOLH1 (0.58) | FOLH1ADRA1ANOD1EPHX2GLP1R | |
| SCHEMBL21078712 | 0.88 | NOD1 (0.56) | FOLH1ADRA1ANOD1EPHX2GLP1R | |
| SCHEMBL21078710 | 0.88 | NOD1 (0.56) | FOLH1ADRA1ANOD1EPHX2GLP1R | |
| SCHEMBL23365799 | 0.87 | NOD1 (0.58) | FOLH1NOD1EPHX2GLP1R | |
| SCHEMBL21172243 | 0.87 | NOD1 (0.58) | FOLH1NOD1EPHX2GLP1R | |
| SCHEMBL20414814 | 0.87 | NOD1 (0.58) | FOLH1NOD1EPHX2GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10039809-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-08-07 | — | — | US | disclosed |
| US-10010589-B2 | — | — | 2018-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010589-B2 | — | TYMP, MTAP, TUBB6 | FOLH1 28/4885ADRA1A 4568/4885NOD1 3613/4885 |
| US-10039809-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | SGMS1, SGMS2, PHOSPHO1 | FOLH1 10/4885ADRA1A 4753/4885NOD1 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.